Skip to main content

Roche mixes Actemra with Gilead's remdesivir in Covid-19 trial

Roche is hoping that by combining the two in a global study of 450 hospitalized patients worldwide, it will be able to offer doctors a one-two punch against the disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.